Skip to main content

Celgene  (CELG) announced that ozanimod, its treatment candidate for patients with relapsing multiple sclerosis, achieved primary test results of reducing patients' annualized relapse rate when compared to Biogen's  (BIIB) Avonex treatment. Monday's announcement sent the stock up nearly 1% premarket. 

"We plan to begin submitting global registration dossiers by the end of the year to bring this oral therapy to patients with relapsing multiple sclerosis," Celgene exec Terrie Curran said. 

Celgene shares are up about 1% year to date, but have risen more than 15% over the past 12 months. 

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP's efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.

Scroll to Continue

TheStreet Recommends